---
company: BRAINSTORM CELL THERAPEUTICS INC.
ticker: BCLI
form: 8-K
filed: 2026-08-14
accession: 0001104659-26-097180
source: https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/
---

# Brainstorm Cell Therapeutics (BCLI) earnings release, August 14, 2026

Brainstorm Cell Therapeutics Inc. (BCLI) · Form 8-K, Item 2.02 · Filed 2026-08-14 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1137883/000110465926097180/)

BrainStorm Cell Therapeutics Announces Second

Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Aug 14, 2026 /PRNewswire/

--

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special

Protocol Assessment,” said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. “The recent appointment of

Peter Pitts as Executive Chairman represents an important enhancement to our leadership. Peter is joining the Company in an active executive capacity and will help lead the regulatory, operational, partnership and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this next phase. ALS imposes an enormous burden on patients, families and caregivers, and we remain resolute in our commitment to the ALS community and to advancing what we believe will be a valuable new therapeutic option.”

Recent Highlights

NurOwn® (MSC-NTF) for ALS

Corporate and Leadership

Publications

Financial Results for the Second Quarter Ended June 30, 2026

U.S. dollars in thousands

(Except share and per share amounts)

The accompanying notes are an integral part of the consolidated financial statements.

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE LOSS (UNAUDITED)

U.S. dollars in thousands

(Except share and per share amounts)

The accompanying notes are an integral part of the consolidated financial statements.

About NurOwn®

The NurOwn® technology platform (autologous

MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary

NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

NurOwn® is BrainStorm’s lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration

(FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the “Floor Effect,” a critical challenge in measuring clinical outcomes in advanced

ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National

MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm’s growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,”

“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”

“potential,” “predict,” “project,” “target,” “aim,” “should,”

“will”, “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation,... (tent’s ability to successfully achieve its goals, BrainStorm’s ability to raise additional capital, BrainStorm’s ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm’s future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investors:

Michael Wood

Phone: +1 646-597-6983 mwood@lifesciadvisors.com

Media:

Uri Yablonka, Chief Business Officer

Phone: +1 917-284-2911 uri@brainstorm-cell.com

## Financial statements

### Income Statement (Six months ended — (Except share and per share amounts) (in thousands))

| | Six months ended – June 30, – 2026 – Unaudited | Six months ended – June 30, – 2025 – Unaudited | Three months ended – June 30, – 2026 – Unaudited | Three months ended – June 30, – 2025 – Unaudited |
|---|---:|---:|---:|---:|
| Operating expenses: | Research and development, net | 1,725 | 2,424 | 963 | 1,120 |
| Operating expenses: | General and administrative | 3,934 | 3,238 | 2,650 | 1,453 |
| Operating expenses: | Operating loss | -5,659 | -5,662 | -3,613 | -2,573 |
| Operating expenses: | Financial income (expense), net | -323 | -284 | -242 | -330 |
| Operating expenses: | Gain (loss) on change in fair value of Warrants liability |  | 179 |  |  |
| Operating expenses: | Net loss | -5,982 | -5,767 | -3,855 | -2,903 |
| Operating expenses: | Basic and diluted net loss per share from continuing operations | -0.54 | -0.77 | -0.35 | -0.34 |
| Operating expenses: | Weighted average number of shares outstanding used in computing basic and diluted net loss per share | 11,034,775 | 7,487,495 | 11,034,775 | 8,620,400 |

### Balance Sheet (December 31, — (Except share and per share amounts) (in thousands))

| | June 30, – 2026 – Unaudited – U.S. $ in thousands | December 31, – 2025 – Audited – U.S. $ in thousands |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 22 | 29 |
| Current Assets: | Other accounts receivable | 162 | 86 |
| Current Assets: | Prepaid expenses and other current assets | 132 | 192 |
| Current Assets: | Total current assets | 316 | 307 |
| Long-Term Assets: | Prepaid expenses and other long-term assets | 27 | 25 |
| Long-Term Assets: | Restricted Cash | 187 | 247 |
| Long-Term Assets: | Right of use asset (Note 3) | 106 | 208 |
| Long-Term Assets: | Property and equipment, net | 152 | 235 |
| Long-Term Assets: | Total Long-Term Assets | 472 | 715 |
| Long-Term Assets: | Total assets | 788 | 1,022 |
| Current Liabilities: | Accounts payable | 7,488 | 7,067 |
| Current Liabilities: | Accrued expenses | 454 | 396 |
| Current Liabilities: | Short-term loans (Note 6) | 1,261 | 967 |
| Current Liabilities: | Operating lease liability (Note 3) | 113 | 208 |
| Current Liabilities: | Employees related liability | 3,069 | 2,369 |
| Current Liabilities: | Total current liabilities | 12,385 | 11,007 |
| Current Liabilities: | Total liabilities | 12,385 | 11,007 |
| Stockholders’ Deficit: | Stock capital: (Note 4) | 16 | 16 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Additional paid-in-capital | 231,428 | 227,058 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Treasury stock | -116 | -116 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Accumulated deficit | -242,925 | -236,943 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Total stockholders’ deficit | -11,597 | -9,985 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Total liabilities and stockholders’ deficit | 788 | 1,022 |
